Sjoukje J C van der Stegen
Overview
Explore the profile of Sjoukje J C van der Stegen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
3236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lindenbergh P, van der Stegen S
Transfus Med Hemother
. 2025 Feb;
52(1):27-41.
PMID: 39944411
Background: The clinical success of autologous adoptive cell therapy (ACT) is substantial but wide application is challenged by the quality and quantity of the patient's immune cells and the need...
2.
Diop M, van der Stegen S
Exp Hematol
. 2024 Sep;
139:104648.
PMID: 39251182
Adoptive cell therapy (ACT) enhances the patient's own immune cells' ability to identify and eliminate cancer cells. Several immune cell types are currently being applied in autologous ACT, including T...
3.
van der Stegen S, Lindenbergh P, Petrovic R, Xie H, Diop M, Alexeeva V, et al.
Nat Biomed Eng
. 2024 Feb;
8(11):1500.
PMID: 38347164
No abstract available.
4.
van der Stegen S, Riviere I
Cell Stem Cell
. 2023 Mar;
30(3):248-249.
PMID: 36868193
The generation of off-the-shelf CAR-T cells from TiPSCs has been hindered by the difficulty to recapitulate adaptive T cell development and lower therapeutic efficacy compared to peripheral blood CAR-T cells....
5.
Cichocki F, van der Stegen S, Miller J
Blood
. 2022 Nov;
141(8):846-855.
PMID: 36327161
The development of methods to derive induced pluripotent stem cells (iPSCs) has propelled stem cell research, and has the potential to revolutionize many areas of medicine, including cancer immunotherapy. These...
6.
van der Stegen S, Lindenbergh P, Petrovic R, Xie H, Diop M, Alexeeva V, et al.
Nat Biomed Eng
. 2022 Aug;
6(11):1284-1297.
PMID: 35941192
The production of autologous T cells expressing a chimaeric antigen receptor (CAR) is time-consuming, costly and occasionally unsuccessful. T-cell-derived induced pluripotent stem cells (TiPS) are a promising source for the...
7.
Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, et al.
Nat Med
. 2022 Jan;
28(2):345-352.
PMID: 35027758
Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune responses. Tumor escape associated with low target antigen expression is emerging as one potential limitation of their efficacy....
8.
van Schalkwyk M, van der Stegen S, Bosshard-Carter L, Graves H, Papa S, Parente-Pereira A, et al.
Cells
. 2021 Aug;
10(7).
PMID: 34359966
Adoptive cancer immunotherapy using chimeric antigen receptor (CAR) engineered T-cells holds great promise, although several obstacles hinder the efficient generation of cell products under good manufacturing practice (GMP). Patients are...
9.
Hamieh M, Dobrin A, Cabriolu A, van der Stegen S, Giavridis T, Mansilla-Soto J, et al.
Nature
. 2019 Mar;
568(7750):112-116.
PMID: 30918399
Chimeric antigen receptors (CARs) are synthetic antigen receptors that reprogram T cell specificity, function and persistence. Patient-derived CAR T cells have demonstrated remarkable efficacy against a range of B-cell malignancies,...
10.
Giavridis T, van der Stegen S, Eyquem J, Hamieh M, Piersigilli A, Sadelain M
Nat Med
. 2018 May;
24(6):731-738.
PMID: 29808005
Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially acute lymphoblastic leukemia (ALL) . Although a majority of patients will achieve a...